Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Finerenone attenuates downregulation of the kidney GLP-1 receptor and glucagon receptor and cardiac GIP receptor in mice with comorbid diabetes ; volume:16 ; number:1 ; day:24 ; month:11 ; year:2024 ; pages:1-15 ; date:12.2024
Diabetology & metabolic syndrome ; 16, Heft 1 (24.11.2024), 1-15, 12.2024
- Urheber
-
Tran, Duc Tin
Yeung, Emily S. H.
Hong, Lisa Y. Q.
Kaur, Harmandeep
Advani, Suzanne L.
Liu, Youan
Syeda, Madiha Zahra
Batchu, Sri Nagarjun
Advani, Andrew
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13098-024-01525-3
- URN
-
urn:nbn:de:101:1-2502092113274.161343838038
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tran, Duc Tin
- Yeung, Emily S. H.
- Hong, Lisa Y. Q.
- Kaur, Harmandeep
- Advani, Suzanne L.
- Liu, Youan
- Syeda, Madiha Zahra
- Batchu, Sri Nagarjun
- Advani, Andrew
- SpringerLink (Online service)
Ähnliche Objekte (12)
Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1
GLP-1/glucagon receptor co-agonism for treatment of obesity
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor
Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
Spatiotemporal GLP-1 and GIP Receptor Signaling and Trafficking/Recycling Dynamics Induced by Selected Receptor Mono- and Dual-agonists
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Synthesis of a Glucagon Receptor Antagonist
Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1
GLP-1/glucagon receptor co-agonism for treatment of obesity
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor
Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
Spatiotemporal GLP-1 and GIP Receptor Signaling and Trafficking/Recycling Dynamics Induced by Selected Receptor Mono- and Dual-agonists
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Synthesis of a Glucagon Receptor Antagonist
Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1
GLP-1/glucagon receptor co-agonism for treatment of obesity
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor
Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
Spatiotemporal GLP-1 and GIP Receptor Signaling and Trafficking/Recycling Dynamics Induced by Selected Receptor Mono- and Dual-agonists
Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain–Adipocyte Axis
Synthesis of a Glucagon Receptor Antagonist
Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide